Drug Trial Radar · NCT06280703
A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)
Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
121
Actual
Start
May 15, 2024
Primary completion
Oct 3, 2026
Study completion Oct 3, 2026
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Feb 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main purpose of this study is to look at the amount of the study drug LY3938577 that gets into the blood stream and how long it takes the body to get rid of it. At a later stage of this study (part B and C) the blood sugar lowering effect and the duration of action of LY3938577 will be evaluated compared to Insulin Degludec. The study will also evaluate the safety and tolerability of LY3938577 and information about any side effects experienced will be collected. The study will be conducted in four parts (A, B, C, and D). Healthy participants in Part A Period 1 will receive a single dose of LY3938577 or a placebo given via intravenous (IV) infusion. In Part A Period 2, participants will receive a single subcutaneous (SC) dose of either LY3938577 or placebo. Participants in Part B with Type 1 Diabetes Mellitus (T1DM) will receive single doses of either LY3938577 or Insulin Degludec given via IV infusion. Participants in Part C with Type 1 Diabetes Mellitus (T1DM) will receive two doses of either LY3938577 or Insulin Degludec administered SC. Participants in Part D with Type 1 Diabetes Mellitus (T1DM) will be evaluated in 2 periods, with Period 1 administered pre-study basal insulin and lispro mealtime insulin to establish insulin needs, and Period 2 administered lispro mealtime insulin and daily doses of LY3938577. The study will last up to approximately 11 weeks for Part A, 10 weeks for Part B, 13 weeks for Part C, and 10 weeks for Part D , including screening period.
Conditions
- Healthy
- Type 1 Diabetes Mellitus
Interventions
LY3938577Drug
Administered Intravenously (IV)
PlaceboDrug
Administered Intravenously (IV)
Insulin DegludecDrug
Administered Intravenously (IV)
Insulin LisproDrug
Administered Intravenously (IV)
LY3938577Drug
Administered subcutaneously (SC)
PlaceboDrug
Administered subcutaneously (SC)
Insulin DegludecDrug
Administered SC
Basal InsulinDrug
Administered subcutaneously (SC)
Lispro Prandial InsulinDrug
Administered subcutaneously (SC)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Number of participants with one or more Adverse Event (s) (AEs), and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration.Time frame: Baseline up to Approximately Week 11
- Part B and D: Number of participants with one or more Adverse Event (s) (AEs), and Serious Adverse Event(s) (SAEs) considered by the investigator to be related to study drug administration.Time frame: Baseline up to Week 10
- Part A: Number of Participants With Clinically Significant Changes in Vital SignsTime frame: Baseline up to Approximately Week 11
- Part B: Number of Participants With Clinically Significant Changes in Vital SignsTime frame: Baseline up to Week 10
- Part A: Number of Participants With Clinically Significant Changes in Safety Laboratory ParametersTime frame: Baseline up to Approximately Week 11
- Part B: Number of Participants With Clinically Significant Changes in Safety Laboratory ParametersTime frame: Baseline up to Week 10
- Part A: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3938577Time frame: Predose on day 1 up to week 13 post dose
- Part A: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3938577Time frame: Predose on day 1 up to week 13 post dose
- Part B: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3938577Time frame: Predose on day 1 up to week 13 post dose
- Part C: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3938577Time frame: Predose on day 1 up to week 13 post dose
- Part D: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3938577Time frame: Predose on day 1 up to week 13 post dose
- Part A: PK: Maximum Observed Concentration (Cmax) of LY3938577Time frame: Predose on day 1 up to week 13 post dose
- Part B: PK: Maximum Observed Concentration (Cmax) of LY3938577Time frame: Predose on day 1 up to week 13 post dose
- Part C: PK: Concentration of LY3938577Time frame: Predose on day 1 up to week 13 post dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Profil Institut für Stoffwechselforschung
Neuss, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.